Alert detail

LCD L36186: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian

Policy ID: LCD-L36186Specialty: HematologyAdded: 6/5/2026Effective: July 16, 2023lcd

High

What changed

Impact on genetic testing billing for myeloproliferative diseases.

Who’s affected: Hematology billing teams · Effective: July 16, 2023

Affected codes

Codes81206 81207 81208 81479 0040U 81170 81219 81270 81279 81338 81339 81450 0027U

DxD47.1 C94.00 C94.02

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 16 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plans Create a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Hematology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Hematology— the week’s changes and deadlines, delivered to your inbox. No account required.